R&D | January 16, 2026
EMA and FDA unveil joint AI principles to transform drug revelopment
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Experts caution that realizing AI’s potential requires careful management and risk mitigation
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
Subscribe To Our Newsletter & Stay Updated
